Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 1:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 567 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Transport Safety Clear all
Terminated Phase 1 Interventional

Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma

NCT03137199
View directory record Official record
Conditions
Asthma
Interventions
hMSCs
Biological
Lead sponsor
Marilyn Glassberg
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

NCT01157364
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2, bimatoprost 6 µg generation 2, bimatoprost 15 µg generation 1, bimatoprost 10 µg generation 1, bimatoprost 0.03%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
36
States / cities
Artesia, California • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Sep 10, 2026, 1:26 AM EDT
Suspended Phase 1Phase 2 Interventional

Dose Safety Hybrid Closed Loop and Fully Automated Closed Loop Artificial Pancreas Device in CRC

NCT03428295
View directory record Official record
Conditions
Glucose, Low Blood, Glucose, High Blood
Interventions
Dose Safety AP system
Device
Lead sponsor
Dose Safety Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Redmond, Washington
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants

NCT00308412
View directory record Official record
Conditions
Paramyxoviridae Infections, Virus Diseases
Interventions
rHPIV3cp45, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 36 Months
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2010 · Synced Sep 10, 2026, 1:26 AM EDT
Recruiting Not applicable Interventional

Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy

NCT05866419
View directory record Official record
Conditions
Spinal Muscular Atrophy, Spine Deformity, Scoliosis
Interventions
ThecaFlex DRx System
Device
Lead sponsor
Alcyone Therapeutics, Inc
Industry
Eligibility
3 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
15
States / cities
Phoenix, Arizona • Orange, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Phase 3 Interventional Results available

Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

NCT01387230
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Sunset, Louisiana • Easley, South Carolina • Spartanburg, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Phase 1 Interventional

Safety Study in Subjects With Leber Congenital Amaurosis

NCT00516477
View directory record Official record
Conditions
Leber Congenital Amaurosis
Interventions
voretigene neparvovec-rzyl
Biological
Lead sponsor
Spark Therapeutics, Inc.
Industry
Eligibility
8 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 1, 2020 · Synced Sep 10, 2026, 1:26 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)

NCT05606614
View directory record Official record
Conditions
Rett Syndrome
Interventions
TSHA-102
Genetic
Lead sponsor
Taysha Gene Therapies, Inc.
Industry
Eligibility
6 Years to 21 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
8
States / cities
Duarte, California • La Jolla, California • Oakland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection

NCT01734850
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Busulfan, Cal-1 modified HSPC, Cal-1 modified CD4+ T lymphocytes
Drug · Biological
Lead sponsor
Calimmune, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Phase 2 Interventional

Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females

NCT00796289
View directory record Official record
Conditions
Infertility
Interventions
GnRH iontophoretic transdermal Lutrepatch, clomiphene citrate, placebo clomiphene citrate, placebo GnRH patch
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 38 Years · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
35
States / cities
Tucson, Arizona • Jonesboro, Arkansas • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2015 · Synced Sep 10, 2026, 1:26 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

NCT07751042
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
STX-003, KEYTRUDA®
Biological
Lead sponsor
Strand Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Scottsdale, Arizona • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Phase 2 Interventional Results available

Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites

NCT03107091
View directory record Official record
Conditions
Cirrhosis, Ascites Hepatic
Interventions
Terlipressin acetate continuous infusion
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

BCG Vaccination Delivered Intradermally, Orally and by Combined Routes

NCT00396370
View directory record Official record
Conditions
Tuberculosis
Interventions
BCG strain Connaught, BCG strain Danish, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Sep 10, 2026, 1:26 AM EDT
Not listed Phase 2 Interventional

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

NCT01273337
View directory record Official record
Conditions
Stroke, Ischemic Stroke, Stroke in Middle Cerebral Artery (MCA)
Interventions
ALD-401, Sham Procedure
Biological · Procedure
Lead sponsor
Aldagen
Industry
Eligibility
30 Years to 83 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
Los Angeles, California • Miami, Florida • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Phase 2 Interventional Results available

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

NCT05232071
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Interventions
Lanifibranor, Placebo, Empagliflozin
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
26
States / cities
Homewood, Alabama • Chandler, Arizona • Conway, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 10, 2026, 1:26 AM EDT
Active, not recruiting Not applicable Interventional

Clinical Study of the Treovance Stent-Graft for Patients With Abdominal Aortic Aneurysms

NCT02009644
View directory record Official record
Conditions
Abdominal Aortic Aneurysm (AAA)
Interventions
Subjects who receive the Treovance stent-graft
Device
Lead sponsor
Bolton Medical
Industry
Eligibility
18 Years to 85 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Danbury, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 10, 2026, 1:26 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Intrathecal ELP-02 for Charcot-Marie-Tooth Disease Type 4J (CMT4J)

NCT07447557
View directory record Official record
Conditions
Charcot-Marie-Tooth Disease Type 4J
Interventions
ELP-02
Genetic
Lead sponsor
Elpida Therapeutics SPC
Industry
Eligibility
3 Years to 20 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Palo Alto, California • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 10, 2026, 1:26 AM EDT
Withdrawn Not applicable Interventional

Study to Assess the Safety and Cardiovascular Effects of Autologous Adipose-Derived Stromal Cells Implantation In Patients During the Acute Recovery Phase of ST-Elevation Myocardial Infarction

NCT01974128
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
ASC isolation and implantation
Procedure
Lead sponsor
Ageless Regenerative Institute
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 10, 2026, 1:26 AM EDT
Active, not recruiting Phase 2 Interventional

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma

NCT03467516
View directory record Official record
Conditions
Uveal Neoplasms, Melanoma, Uveal
Interventions
Tumor Infiltrating Lymphocytes (TIL)
Biological
Lead sponsor
Udai Kammula
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Phase 3 Interventional Results available

Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension

NCT00709098
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
iloprost
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
32
States / cities
La Jolla, California • Sacramento, California • Torrance, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Phase 3 Interventional Results available

Single-arm Study to Assess the Safety of Hydromorphone Hydrochloride by Intrathecal Administration

NCT01709747
View directory record Official record
Conditions
Chronic Pain
Interventions
Hydromorphone Hydrochloride, Programmable Implantable pump
Drug · Device
Lead sponsor
Piramal Critical Care, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vaginal Delivery Debrief Checklist to Improve Team Communication

NCT01822158
View directory record Official record
Conditions
Other Specified Complications of Labor and Delivery
Interventions
Vaginal Delivery Debrief Checklist
Other
Lead sponsor
Providence Health & Services
Other
Eligibility
Not listed
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Olympia, Washington
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects

NCT02601625
View directory record Official record
Conditions
Safety, Pharmacokinetics, Healthy Subjects
Interventions
Anifrolumab SC injection (300mg), Anifrolumab IV infusion (300mg), Anifrolumab SC infusion (600mg), Anifrolumab placebo SC injection (300mg), Anifrolumab placebo IV infusion (300mg), Anifrolumab placebo SC infusion (600mg)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 10, 2026, 1:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants

NCT06058390
View directory record Official record
Conditions
Hepatitis B
Interventions
Bepirovirsen
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 10, 2026, 1:26 AM EDT